论文信息 - Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC. - 字舞流文

Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC.

Kenya Yamaguchi | M. Oya | Y. Tomita | N. Shinohara | W. Obara | H. Matsuyama | T. Saika | R. Shiroki | Masayuki Takahashi | H. Kanayama | T. Koie | T. Ueda | S. Naito | T. Kishida | J. Teishima | Yasuyuki Kobayashi | N. Sassa | T. Kondo | Atsushi Takahashi